Hesseling P B
Department of Paediatrics and Child Health, Tygerberg Hospital, University of Stellenbosch, Republic of South Africa.
Trans R Soc Trop Med Hyg. 1991 Jan-Feb;85(1):131-2. doi: 10.1016/0035-9203(91)90186-3.
Onyalai, a form of immune thrombocytopenia in Africa, has a recorded death rate of 9.8% in the acute phase due to haemorrhagic shock or central nervous system bleeding. Four patients with active bleeding and a mean platelet count of 6 x 10(9)/litre were each treated with 0.67 g/kg intravenous globulin (Sandoglobulin) daily on 3 successive days. Clinical bleeding ceased within 3 d and all patients responded with a rise in the platelet count, which peaked at 19-21 d. No side effect was recorded. Intravenous globulin therapy may reduce the morbidity of the acute phase of onyalai.
奥尼亚莱是非洲免疫性血小板减少症的一种形式，急性期因失血性休克或中枢神经系统出血，记录的死亡率为9.8%。4例有活动性出血且平均血小板计数为6×10⁹/升的患者，连续3天每天接受0.67克/千克静脉注射球蛋白（桑多球蛋白）治疗。临床出血在3天内停止，所有患者血小板计数均升高，在19 - 21天达到峰值。未记录到副作用。静脉注射球蛋白治疗可能会降低奥尼亚莱急性期的发病率。
